Therapies targeting epidermal growth factor receptor (EGFR), such as erlotinib, gefitinib, and osimertinib (EGFR inhibitors), have been found to be more adapted for EGFR-mutated NSCLC patients [24]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.